Would you advocate for SGLT2 inhibitors if they are not fully covered by insurance in patients with moderately increased albuminuria (< 300 mg/g) who are on maximal dose ACEi/ARB?

I think the benefit would be minimal. I would not necessarily have the patient pay extra money to get them.

If the reduction of proteinuria is the goal, consider using a non-hydropyridine calcium channel blocker such as diltiazem. It is cheaper than a SGLT2I.